Premium
Medical treatment of recurrent ischaemic priapism: a review of current molecular therapeutics and a new clinical management paradigm
Author(s) -
Joice Gregory A.,
Liu James L.,
Burnett Arthur L.
Publication year - 2021
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.15370
Subject(s) - medicine , priapism , intensive care medicine , clinical trial , disease , quality of life (healthcare) , bioinformatics , surgery , pathology , nursing , biology
Objectives To examine the current molecular therapeutics in the medical treatment of recurrent ischemic priapism (RIP). To propose a stepwise clinical management paradigm for the treatment of RIP. Methods We performed a literature search using the PubMed database for the terms ‘recurrent ischemic priapism’ and ‘stuttering priapism’ up until December 2020. We assessed pre‐clinical and clinical studies regarding medical management of RIP and molecular pathophysiology. Case series and randomized trials were evaluated by study quality and patient outcomes to determine a potential clinical management scheme. Results Recent research has fostered an improved understanding of the underlying molecular pathophysiology of RIP that has paved the way forward for developing new therapeutic agents. Medications targeting neurovascular, hormonal and haematological mechanisms associated with RIP show great promise towards remedying this condition. A host of therapeutic agents operating across different mechanistic directions may be implemented according to a clinical management scheme to potentially optimize RIP outcomes. Conclusion RIP remains a medically neglected condition with current management focused on treating the acute condition rather than modulating the course of disease. Continued research into the molecular mechanisms of RIP and standardized clinical pathways can improve the quality of care for patients suffering from this condition.